Observational studyEuropean journal of nuclear medicine and molecular imaging2022
A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Observational study in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04317313 (Synergistic Effect of 18F-FDG PET Radiomics and International Prognostic Index on Outcome Prediction in Diffuse Large B-cell Lymphoma), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Synergistic Effect of 18F-FDG PET Radiomics and International Prognostic Index on Outcome Prediction in Diffuse Large B-cell Lymphoma
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Multi-Modal Ultrasound-Based Prognostic Model for Diffuse Large B-Cell Lymphoma with Predominantly Superficial Lymph Node Involvement.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.BMC medicine · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Automatic Lugano staging for risk stratification in lymphoma: a multicenter PET radiomics and machine learning study with survival analysis.Nuclear medicine communications · 2025Article
- Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- A proof of concept study ofScientific reports · 2025Article
- The 13th World Federation of Nuclear Medicine and Biology congress (WFNMB 2022): summarize the past half century and discuss the next half century of WFNMB.Annals of nuclear medicine · 2025Article
- BaselineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Radiomics based onQuantitative imaging in medicine and surgery · 2025Article
- Prognostic assessment of diffuse large B-cell lymphoma using ultrasound imaging nomogram and PET/CT indicators.Frontiers in oncology · 2025Article
- Enhancing precision in lymphoma detection with novel deep transformer-based neural networks.PloS one · 2025Article
- The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic.Cancer management and research · 2025Review
- Review
- Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combiningPediatric radiology · 2024Article
- Methodological evaluation of original articles on radiomics and machine learning for outcome prediction based on positron emission tomography (PET).Nuklearmedizin. Nuclear medicine · 2023Review
- Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.BMC cancer · 2023Article
- The remodeling of metabolic brain pattern in patients with extracranial diffuse large B-cell lymphoma.EJNMMI research · 2023Article
- BaselineEJNMMI research · 2023Article
- Prognostic value of whole-body dynamicHeliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to develop a novel analytic approach based on 2-deoxy-2-[
methodsWe retrospectively enrolled 152 DLBCL patients and divided them into a training cohort (n = 100) and a validation cohort (n = 52). A total of 1245 radiomic features were extracted from the total metabolic tumor volume (TMTV) and the metabolic bulk volume (MBV) of pre-treatment PET/CT images. The least absolute shrinkage and selection operator (LASSO) algorithm was applied to develop the RS. Cox regression analysis was used to construct hybrid nomograms based on different RS and clinical variables. The performances of hybrid nomograms were evaluated using the time-dependent receiver operator characteristic (ROC) curve and the Hosmer-Lemeshow test. The clinical utilities of prediction nomograms were determined via decision curve analysis. The predictive efficiency of different RS, clinical variables, and hybrid nomograms was compared.
resultsThe RS and IPI were identified as independent predictors of PFS and OS, and were selected to construct hybrid nomograms. Both TMTV- and MBV-based hybrid nomograms had significantly higher values of area under the curve (AUC) than IPI in training and validation cohorts (all P < 0.05), while no significant difference was found between TMTV- and MBV-based hybrid nomograms (P > 0.05). The Hosmer-Lemeshow test showed that both TMTV- and MBV-based hybrid nomograms calibrated well in the training and validation cohorts (all P > 0.05). Decision curve analysis indicated that hybrid nomograms had higher net benefits than IPI.
conclusionThe hybrid nomograms combining RS with IPI could significantly improve survival prediction in DLBCL. Radiomic analysis on MBV may serve as a potential approach for prognosis assessment in DLBCL.
trial registrationNCT04317313. Registered March 16, 2020. Public site: https://clinicaltrials.gov/ct2/show/NCT04317313.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.